- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02349763
Dexamethasone Regimens for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction (DEPARO)
Intravenous Versus Oral Regimens of Dexamethasone for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction in Primary Ovarian, Fallopian Tube and Peritoneal Cancer Patients: a Double-blind Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The consensus statements on the management of ovarian cancer recommended intravenous paclitaxel (175 mg/m2 over 3 hr) plus intravenous carboplatin (area under the curve [AUC] 5.0-7.5 mg/ml∙min) given every 3 weeks for six cycles for first-line chemotherapy. A major limitation of paclitaxel was its poor water solubility, which led to the use of polyoxyethylated castor oil vehicle or Cremophor® EL as diluents resulted a hypersensitivity reactions (HSRs). Initial P-HSRs generally occur within 10 minutes of the start of paclitaxel infusion and most occur with the first or second infusion. Majority of patients manifest as minor symptoms characterized by flushing and rashes but sometime life-threatening characterized by generalized urticaria, angioedema, bronchospasm and hypertension or until fatal may occur. The reaction is likely due to the release of histamine and other vasoactive substances in response to Cremophor EL. Originally, the prophylactic regimen composed of the use of an oral corticosteroid administered in two doses at 12 and 6 hours prior to paclitaxel infusion accompanied with histamine receptor H1 and H2 antagonists administered intravenously 30 minutes prior to paclitaxel infusion was found to successfully limit P-HSRs denoted as "Conventional oral prophylactic regimen".
While this three-drug prophylactic regimen has been shown to be effective, it can be inconvenient for patients because the oral corticosteroid must be taken 12 and 6 hours before chemotherapy administration. If the patient forgets to take one or both pretreatment steroid doses, it is not clear whether the patient can be safely treated. This led to the experimental prophylactic regimen of one dose of intravenous dexamethasone accompanied with the H1 and H2 antagonists administered 30 minutes prior to paclitaxel infusion was subsequently reported to be equivalent to the regimen of oral dexamethasone denoted as "Modified intravenous prophylactic regimen". This intravenous regimen results in lower total steroid doses and precludes the issues of compliance.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand, 10400
- Rajavithi Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient pathologically diagnosed with primary ovarian or fallopian tube or peritoneal cancer
- Patient starting a first cycle of combination paclitaxel and carboplatin at Rajavithi Hospital between February 1, 2015 and July 31, 2015
- Patient aged 18-70 years
- Patient with ECOG performance status 0-2
- Patient with the following laboratory values obtained: Hemoglobin > 10 g/dL, Absolute neutrophil count > 1500 /mm3, Platelet count > 100,000/mm3, Serum creatinine > 2.0 mg/dL, Bilirubin > 1.5 x ULN, alkaline phosphatase and SGOT > 3 x ULN
- Patient able to give free and informed consent and who agrees to participate by signing the consent form
- Patient able to speak and understand Thai
- Patient able to complete the quality of life questionnaire on Functional Assessment of Cancer Therapy - Ovarian Cancer (FACT-O) Thai version 4.0 and the personal logbook
Exclusion Criteria:
- Patient who has previously received paclitaxel or carboplatin
- Patient receiving an albumin-bound paclitaxel
- Patient who had an allergic reaction to taxanes or platinum analogues
- Patient is currently under treatment with systemic corticosteroids or has received systemic corticosteroids or histamine antagonists during the last week
- Patient who had an allergic reaction to corticosteroid or diphenhydramine or ranitidine
- Patient with severe intolerance to lactose
- Patient with an allergy or a severe intolerance to products containing castor oil e.g. cyclosporine, teniposide, diazepam, propofol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Oral Dexamethasone
Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
|
Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
Other Names:
|
Experimental: Intravenous Dexamethasone
Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
|
Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Paclitaxel-Associated Hypersensitivity Reaction (P-HSRs) and severe P-HSRs (Safety endpoint)
Time Frame: 3 Hours after starting paclitaxel infusion
|
The participants are received either intravenous dexamethasone or placebo (0.9% NaCL) at 09.30 am (30 minutes before paclitaxel infusion) depend on intervention groups.
Intravenous ranitidine 50 mg and diphenhydramine 50 mg are also given all participants.
Paclitaxel is started at 10.00 am by the calculated dose of is diluted in 500 ml of saline and administered by intravenous infusion over 3 hours.
|
3 Hours after starting paclitaxel infusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of side effects of dexamethasone
Time Frame: 1 week after completion of chemotherapy
|
All participants receive the personal logbook for self-administration of side effects from dexamethasone in day 1-7
|
1 week after completion of chemotherapy
|
Incidence of other Adverse Events ( according to NCI CTCAE version 4.03)
Time Frame: Adverse events were measured at Day 1 and Day 28 of intervention
|
The adverse events are collected according to NCI CTCAE version 4.03.
|
Adverse events were measured at Day 1 and Day 28 of intervention
|
Quality of life (QoL) (assessed by FACT-O score)
Time Frame: QoL is measured at Day 0 and Day 28 of intervention
|
Quality of life assessed by FACT-O score
|
QoL is measured at Day 0 and Day 28 of intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Dr Marut Yanaranop, MD, Rajavithi Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Hypersensitivity
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Protease Inhibitors
- Dexamethasone
- Dexamethasone acetate
- BB 1101
Other Study ID Numbers
- pHSR01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypersensitivity Reaction
-
Université de SherbrookeTerminatedAnaphylaxis | Biphasic Anaphylactic Reaction | Rebound Anaphylactic ReactionCanada
-
Medical University of BialystokCompletedHypersensitivity Reaction
-
Hospices Civils de LyonCompletedAnaphylaxis | Allergic ReactionFrance
-
Centre Hospitalier Régional Metz-ThionvilleCompleted
-
Groupe Hospitalier Paris Saint JosephActive, not recruitingAllergic Reaction | Beta Lactam Adverse ReactionFrance
-
University Hospital, AntwerpNot yet recruitingHypersensitivity | Anaphylaxis | Allergic Reaction | Perioperative Complication | Immediate Hypersensitivity | Hypersensitivity, Drug | Anaphylactic ReactionBelgium
-
University Hospital, GrenobleTerminatedAllergic Hypersensitivity Drug Reaction Versus Non-allergic Hypersensitivity Drug Reaction Cross ReactionFrance
-
Nasus PharmaHadassah Medical Organization; Pharma Medica Research, Inc.; Medistat Ltd., IsraelCompleted
-
Charite University, Berlin, GermanyRecruitingAnaphylaxisGermany
-
University Hospital, MontpellierRecruiting
Clinical Trials on Oral Dexamethasone
-
Bristol-Myers SquibbRecruitingMyelodysplastic SyndromesUnited States, Japan, Argentina, Hong Kong, Greece, Italy, China, Australia, Spain, Austria, Denmark, Germany, Sweden, Switzerland, Canada, Czechia, Korea, Republic of, Poland, Turkey, France
-
Hospital Son EspasesRecruitingTraumatic Brain Injury | Cerebral EdemaSpain
-
University of ArizonaUnknownDental Research | Pharmaceutical Preparations, DentalUnited States
-
Ain Shams UniversityAlexandria University; Cairo University; Assiut University; Suez Canal University; Menia UniversityUnknown
-
Vanderbilt University Medical CenterTerminatedAsthma | CroupUnited States
-
GlaxoSmithKlineCompletedNausea and Vomiting, Chemotherapy-InducedUnited States
-
Seoul National University HospitalWithdrawnAcute BronchiolitisKorea, Republic of
-
Rajshekhar Chakraborty, MDGenentech, Inc.RecruitingAL AmyloidosisUnited States
-
May SamahaRecruitingIrreversible PulpitisLebanon
-
Hamad Medical CorporationRecruiting